FindTrial
Sign In

Comparison of Second-Line Hormonal Agents Medroxyprogesterone Acetate and Aminoglutethimide in Advanced Breast Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN44725655
Enrollment
Unknown
Registered
2002-08-19
Start date
1991-08-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Cancer Breast Cancer

Interventions

Patients are randomised to receive: 1. Group A: Medroxyprogesterone acetate 250 mg four times daily until disease progression or failure of treatment. 2. Group B: Aminoglutethimide 250 mg twice daily

Sponsors

Ciba-Geigy Pharmaceuticals (Switzerland)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Advanced breast cancer 2. Relapsed or failed following tamoxifen treatment 3. Postmenopausal

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration.—

Secondary

MeasureTime frame
Not provided at time of registration.—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026